Sponsor
Eisai Australia
15 PBAC submissions on file, active 2007–2018. 60% have been recommended.
Submissions
15
2007 → 2018
Win rate
60 %
9 recommended of 15 bucketable
Drugs
5 · 5 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Lenvatinib
Hepatology · Recommended · 2018 — Perampanel
Neurology · Recommended with restriction · 2017 — Eribulin mesilate
Oncology · Recommended with restriction · 2013 — Eribulin
Oncology · Recommended with restriction · 2016 — Zonisamide
Neurology · Recommended with restriction · 2007 — Therapy area mix Oncology 9 Neurology 4 Hepatology 2
Activity by year 2007 (1) · 2013 (2) · 2014 (1) · 2015 (1) · 2016 (4) · 2017 (2) · 2018 (4)
Rejection patterns
Across 6 Not recommended decisions on file.
1× unacceptably high and uncertain cost-effectiveness1× lack of clarity regarding clinical place of the product1× uncertain cost-effectiveness estimate1× insufficient support for non-inferior toxicity claim1× inadequate capture of treatment disutilityOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.